-------------------------------------------------------ABSTRACT ---------------------------------------------------
Usually the main problem face any investigation it how to determent a sample size, however, some
considerations required in sample size to conduct the efficacy and make realistic well-researched before began
study. This study aimed to determine the maximum possible sample size at different phases of clinical trials and
attempt to achieve the best accuracy of the results. To achieve that the maximum sample size in different phases
we found that the maximum sample size of phase I was (75) relies on largest response rate 20% and the minimal
clinically important difference (MCID) 15%, and because the participants are healthy often that means 15%
enough to show positive results of the transition to the second phase. for the phase II clinical trials; the
maximum sample size was (388) depend on the error 5% and largest response rate 50% when the response rate
should not be less than 20% according to the design used in this phase. Depend on the endpoint and hazard
ratio in phase III clinical trials when the probability of survival of the treatment group equal to median of the
probability of survival 50% we found that the maximum sample size (4796). For the phase IV the maximum
sample size in different phases of clinical trials does not affect whatever the large of the population size and
remains constant as large as possible size.
Emerging diagnostic technologies proving the clinical application through g...Lyssa Friedman
Next Generation Sequencing is an exciting new technology for diagnostics companies. But is it right for all products and for all companies? This presentation was delivered via Webinar for a IVD audience for Q1 Productions, March 25, 2014.
Academic Report on Japan Clinical Trial Strategy for a Class III Medical DeviceAsia Medical Supplies
The document summarizes the clinical trial strategy for Axcis Plus, a Class III medical device developed by Japan Med to treat refractory angina. Japan Med plans to conduct a phase 3 randomized controlled trial in Japan to evaluate the device's safety and efficacy. The trial will enroll 84 patients and compare outcomes between an intervention group receiving Axcis Plus treatment and a control group. Primary endpoints will assess safety, while secondary endpoints will evaluate effectiveness and secondary assessments. Challenges include physician technique dependence and ensuring accurate data collection. The trial must comply with Japanese good clinical practice regulations and be approved by regulatory agencies.
LBDA: Ask the Expert - Daniel Kaufer Live Webinar June 2016wef
Clinical trials are research studies that test new medical treatments and are conducted according to a research plan called a protocol. A clinical trial has a principal investigator and research team who are responsible for overseeing the trial. Participants must meet eligibility criteria and provide informed consent to enroll. The trial follows a treatment plan, which may involve experimental treatments, standard treatments, or placebos. Participants are monitored by an Institutional Review Board to ensure safety and ethical treatment. Clinical trials provide information about new treatments and help advance medical knowledge, but may not directly benefit participants.
The document discusses key concepts in analyzing clinical trials, including:
- Intention-to-treat analysis, which analyzes all participants based on initial treatment assignment regardless of compliance, and measures effectiveness. This is the recommended primary analysis method.
- Per-protocol analysis, which only includes compliant participants, and measures maximum efficacy. This undermines randomization.
- Measures of effect size such as relative risk, absolute risk reduction, relative risk reduction, and number needed to treat, which are used to assess clinical significance beyond just statistical significance.
- The importance of assessing both statistical and clinical significance of trial results, where clinical significance considers the minimum clinically meaningful effect.
This document discusses various types of endpoints used in clinical research trials. It defines endpoints as the final outcomes measured to assess a drug's efficacy or safety. Endpoints are classified as primary or secondary. Primary endpoints directly answer the main trial questions, while secondary endpoints are analyzed post-hoc. Endpoints can also be hard or soft, composite, surrogate, clinical, or related to mortality, morbidity, quality of life, or patient-reported outcomes. The document provides examples of endpoints used in oncology trials like overall survival and progression-free survival.
Simplifying study designs and statistical models for new dose & dosage forms ...Bhaswat Chakraborty
This document discusses study designs for evaluating the bioequivalence of new drug doses and dosage forms through pharmacokinetic or pharmacodynamic studies. It covers topics such as parallel vs. crossover study designs, sample size calculations, evaluating modified release dosage forms, and considering food effects and non-linear pharmacokinetics. The document also discusses using in vitro studies like dissolution testing and permeation studies to establish bioequivalence for some drug products like topical creams when in vivo studies are challenging.
White_Paper_Synthesis of Adaptive Designs in Clinical Trials_May2016.PDFvbartekian
1. The document discusses various types of adaptive designs that can be used in clinical trials, highlighting their advantages and disadvantages for both exploratory and confirmatory phases.
2. Key challenges of adaptive designs include increased operational complexity, concerns about bias and controlling type 1 errors, and difficulties satisfying regulatory authorities due to limited guidance.
3. The document provides tables summarizing different adaptive designs for exploratory and confirmatory phases, noting their appropriateness, benefits, and drawbacks in each trial context.
Emerging diagnostic technologies proving the clinical application through g...Lyssa Friedman
Next Generation Sequencing is an exciting new technology for diagnostics companies. But is it right for all products and for all companies? This presentation was delivered via Webinar for a IVD audience for Q1 Productions, March 25, 2014.
Academic Report on Japan Clinical Trial Strategy for a Class III Medical DeviceAsia Medical Supplies
The document summarizes the clinical trial strategy for Axcis Plus, a Class III medical device developed by Japan Med to treat refractory angina. Japan Med plans to conduct a phase 3 randomized controlled trial in Japan to evaluate the device's safety and efficacy. The trial will enroll 84 patients and compare outcomes between an intervention group receiving Axcis Plus treatment and a control group. Primary endpoints will assess safety, while secondary endpoints will evaluate effectiveness and secondary assessments. Challenges include physician technique dependence and ensuring accurate data collection. The trial must comply with Japanese good clinical practice regulations and be approved by regulatory agencies.
LBDA: Ask the Expert - Daniel Kaufer Live Webinar June 2016wef
Clinical trials are research studies that test new medical treatments and are conducted according to a research plan called a protocol. A clinical trial has a principal investigator and research team who are responsible for overseeing the trial. Participants must meet eligibility criteria and provide informed consent to enroll. The trial follows a treatment plan, which may involve experimental treatments, standard treatments, or placebos. Participants are monitored by an Institutional Review Board to ensure safety and ethical treatment. Clinical trials provide information about new treatments and help advance medical knowledge, but may not directly benefit participants.
The document discusses key concepts in analyzing clinical trials, including:
- Intention-to-treat analysis, which analyzes all participants based on initial treatment assignment regardless of compliance, and measures effectiveness. This is the recommended primary analysis method.
- Per-protocol analysis, which only includes compliant participants, and measures maximum efficacy. This undermines randomization.
- Measures of effect size such as relative risk, absolute risk reduction, relative risk reduction, and number needed to treat, which are used to assess clinical significance beyond just statistical significance.
- The importance of assessing both statistical and clinical significance of trial results, where clinical significance considers the minimum clinically meaningful effect.
This document discusses various types of endpoints used in clinical research trials. It defines endpoints as the final outcomes measured to assess a drug's efficacy or safety. Endpoints are classified as primary or secondary. Primary endpoints directly answer the main trial questions, while secondary endpoints are analyzed post-hoc. Endpoints can also be hard or soft, composite, surrogate, clinical, or related to mortality, morbidity, quality of life, or patient-reported outcomes. The document provides examples of endpoints used in oncology trials like overall survival and progression-free survival.
Simplifying study designs and statistical models for new dose & dosage forms ...Bhaswat Chakraborty
This document discusses study designs for evaluating the bioequivalence of new drug doses and dosage forms through pharmacokinetic or pharmacodynamic studies. It covers topics such as parallel vs. crossover study designs, sample size calculations, evaluating modified release dosage forms, and considering food effects and non-linear pharmacokinetics. The document also discusses using in vitro studies like dissolution testing and permeation studies to establish bioequivalence for some drug products like topical creams when in vivo studies are challenging.
White_Paper_Synthesis of Adaptive Designs in Clinical Trials_May2016.PDFvbartekian
1. The document discusses various types of adaptive designs that can be used in clinical trials, highlighting their advantages and disadvantages for both exploratory and confirmatory phases.
2. Key challenges of adaptive designs include increased operational complexity, concerns about bias and controlling type 1 errors, and difficulties satisfying regulatory authorities due to limited guidance.
3. The document provides tables summarizing different adaptive designs for exploratory and confirmatory phases, noting their appropriateness, benefits, and drawbacks in each trial context.
This document provides an overview of how to study drug use problems by examining quantitative and qualitative data sources. It describes the components of a drug use system and the process for changing drug use, including examining existing practices, diagnosing specific problems and causes, designing and implementing interventions, and following up to measure changes in outcomes. The document also discusses how to collect data on drug use encounters using various quantitative and qualitative methods and the types of data that can be obtained from different sources like health facilities, private pharmacies, and households.
One size does not fit all unique study management challenges for diagnostic ...Lyssa Friedman
When partnering with a CRO, diagnostic company needs are different from those of pharmaceutical and device companies. This presentation was delivered at Outsourcing in Clinical Trials West Coast 2015, February 3-4, Burlingame, California.
Clinical trials are scientific studies that test new drugs in human subjects. This document discusses the multi-phase clinical trial process, from pre-clinical animal studies through post-approval monitoring. It notes that trials progress from small Phase I safety studies in healthy volunteers to large Phase III efficacy trials in patients. The goal is to demonstrate a drug's benefits outweigh its risks before regulatory approval and marketing.
This document summarizes an introduction to clinical trials presented by Jan B. Vermorken. It outlines the process of moving new cancer therapies from the laboratory to clinical trials, including preclinical testing requirements, phases of clinical trials (I-III), response criteria, and considerations for trials of non-cytotoxic agents. It also discusses the roles and functions of ethics committees in overseeing clinical trials to protect participants.
Developing the Reimbursement Story 2016-03-10Lyssa Friedman
The document discusses strategies for developing a reimbursement case for molecular diagnostic tests early in development. It emphasizes designing analytic and clinical validity studies to demonstrate test accuracy and association with clinical conditions. Clinical utility studies should show how test results impact patient management, outcomes, and healthcare costs. Randomized controlled trials provide the strongest evidence but alternative study designs like prospective observational studies and decision modeling may also support reimbursement. The goal is to generate evidence of a test's medical necessity from the intended patient population to achieve coverage and payment.
Protocol Design & Development: What You Need to Know to Ensure a Successful S...Brook White, PMP
Solid protocol design is critical to clinical development. No matter how well executed a clinical study is, if the underlying design is flawed, it wasn’t worth doing. In this presentation, Dr. David Shoemaker, SVP R&D, and Dr. Karen Kesler, AVP Operations, will walk through the process of developing a protocol, explain the major considerations, and point out common mistakes and challenges.
High variability in PK can be a characteristic of certain drug products which require different from ordinary strategies and study designs for establishing bioequivalence.
This document discusses modern quality management. It provides an overview of tools and strategies for modern quality management, including quality management forms, ISO templates, key performance indicators, and interview questions. It also discusses the contents of modern quality management, focusing on using quality techniques to identify weak points within complex processes and assess the patient benefits of laboratory testing. Three common quality management tools are also summarized: check sheets for collecting real-time data, control charts for monitoring process stability and variation, and Pareto charts for displaying frequency and cumulative totals of problems or issues.
Prescription event monitoring and record linkage systemVineetha Menon
This document discusses record linkage and its use in pharmacovigilance. Record linkage involves combining records from different data sources that relate to the same individual to create a single longitudinal record. It allows rapid access to a patient's complete medical history across different data sources. This reduces the time needed to study relationships between drug exposure and health outcomes. Challenges include ensuring data quality and completeness when integrating records from various sources.
This document discusses adaptive clinical trials. Adaptive trials allow changes to the trial design based on interim data analysis in order to make the trial more efficient. Key aspects that can be adapted include sample size, treatments, endpoints, and eligibility criteria. Adaptive designs are well-suited for exploratory trials aimed at learning, but confirmatory trials require more prior data and safeguards to ensure the trial's integrity and the validity of its conclusions. The FDA has provided guidance on adaptive designs to ensure patient safety and that adaptive trials meet evidentiary standards for approval.
Real effectiveness medicine pursuing best effectiveness in the ordinary care ...Malmivaara Antti
These slides present a new concept of Real-Effectiveness Medicine (REM), which pursues the best effectiveness of patient care in the real-world setting. In order to reach the goal, four layers of information are needed: 1) expertise or the health care personnel, 2) use of up-to-date scientific evidence, 3) continuous documentation of performance and quality improvement, and 4) benchmarking between providers. The new framework is suggested for clinicians, organizations, policy-makers, and researchers.
This presentation explains the main features of medicines which will be developed and authorised via the adaptive pathways. It provides a definition of real world evidence and the caveats associated with the use and analysis of real world evidence in drug development.
Reasons for conducting clinical trialsJohn Douglas
To explain in simple terms, a clinical trail is a research in human volunteers to answer certain health questions. Carefully conducted clinical trails are the quickest and safest way to discover new treatment
methods that work in people and enhance their health.
This document summarizes a presentation given on the case of high correlation but low reliability in point-of-care monitoring of Coumadin therapy. The presentation describes a situation where a community hospital implemented point-of-care testing (POCT) instruments to monitor patients' PT/INR levels in order to adjust Coumadin dosages during visits. While validation studies showed good correlation between the POCT instruments and the laboratory instruments, clinical staff began experiencing unexpected bleeding events in patients. An investigation revealed that though the instruments showed acceptable validation results, the POCT results were less reliable than indicated, especially near medical decision points. This highlighted that validation studies do not necessarily guarantee reliability in POCT. The presentation aims to provide a risk
The late phase research environment has become more complex due to increased regulatory demands from the FDA and EMA for comprehensive safety data. Sponsors must begin planning late phase studies earlier in the investigative process and work with strategic research partners to effectively plan studies that address therapeutic, regulatory and economic concerns. Failing to take early action can result in costly delays and failure to obtain drug approval. Effective planning is essential to navigating today's complex late phase research landscape.
Educating the Next Generation Pharmacist for Industry. The Panjab University ...Ajaz Hussain
The Panjab University Pharmaceutical Science Oration 2014: Educating the Next Generation Pharmacist for Industry.
“The dream begins with a teacher who believes in you, who tugs and pushes and leads you to the next plateau, sometimes poking you with a sharp stick called ‘truth’.“
Plato, the Republic
What are the most influential ideas, concepts, and developments introduced by ‘pharmaceutical scientists’ over the last 50 years?
How have these ideas/concepts introduced into practice?
How can we improve?
Clinical trials are essential for testing the safety and efficacy of new drugs and medical devices. There are typically 4 phases of clinical trials for drugs, beginning with small safety trials and progressing to large efficacy trials. Medical device trials follow a similar progression but do not use placebos and must compare to existing standards of care. Clinical trials are expensive, with medical device trials costing on average $30,000-$40,000 per enrolled patient. Careful design and management can help minimize costs while still obtaining necessary data.
SDTM Training for personnel with Junior and Intermediate level Clinical Trial Experience. Covers summary of most domains. Salient features include order of domain creation, importance of making programming Data/Metadata Driven, Nature of Clinical Raw Data, Summary of the Clinical Trial process with regards to the data flow to arrive at the Study data to be submitted to regulatory authorities like FDA, Importance of deriving ADAM from SDTM and not directly from raw data, Information has been put together from variety of sources including my own programming work.
Adithyaelearning provides SAS CDM Online Training to the candidates having knowledge in the SAS. Throughout this course the participants will become qualified on the Clinical programming models as well as their usage in field of clinical research. The center areas for the course incorporate data integration, data manipulation, data listings production, figures and tables as per Statistical Examination Plan, as well as generation of reports and graphs. Besides this participants can be trained based on fundamental principles as well as concepts in the statistical methodology as well as clinical trials.
This document provides an overview of how to study drug use problems by examining quantitative and qualitative data sources. It describes the components of a drug use system and the process for changing drug use, including examining existing practices, diagnosing specific problems and causes, designing and implementing interventions, and following up to measure changes in outcomes. The document also discusses how to collect data on drug use encounters using various quantitative and qualitative methods and the types of data that can be obtained from different sources like health facilities, private pharmacies, and households.
One size does not fit all unique study management challenges for diagnostic ...Lyssa Friedman
When partnering with a CRO, diagnostic company needs are different from those of pharmaceutical and device companies. This presentation was delivered at Outsourcing in Clinical Trials West Coast 2015, February 3-4, Burlingame, California.
Clinical trials are scientific studies that test new drugs in human subjects. This document discusses the multi-phase clinical trial process, from pre-clinical animal studies through post-approval monitoring. It notes that trials progress from small Phase I safety studies in healthy volunteers to large Phase III efficacy trials in patients. The goal is to demonstrate a drug's benefits outweigh its risks before regulatory approval and marketing.
This document summarizes an introduction to clinical trials presented by Jan B. Vermorken. It outlines the process of moving new cancer therapies from the laboratory to clinical trials, including preclinical testing requirements, phases of clinical trials (I-III), response criteria, and considerations for trials of non-cytotoxic agents. It also discusses the roles and functions of ethics committees in overseeing clinical trials to protect participants.
Developing the Reimbursement Story 2016-03-10Lyssa Friedman
The document discusses strategies for developing a reimbursement case for molecular diagnostic tests early in development. It emphasizes designing analytic and clinical validity studies to demonstrate test accuracy and association with clinical conditions. Clinical utility studies should show how test results impact patient management, outcomes, and healthcare costs. Randomized controlled trials provide the strongest evidence but alternative study designs like prospective observational studies and decision modeling may also support reimbursement. The goal is to generate evidence of a test's medical necessity from the intended patient population to achieve coverage and payment.
Protocol Design & Development: What You Need to Know to Ensure a Successful S...Brook White, PMP
Solid protocol design is critical to clinical development. No matter how well executed a clinical study is, if the underlying design is flawed, it wasn’t worth doing. In this presentation, Dr. David Shoemaker, SVP R&D, and Dr. Karen Kesler, AVP Operations, will walk through the process of developing a protocol, explain the major considerations, and point out common mistakes and challenges.
High variability in PK can be a characteristic of certain drug products which require different from ordinary strategies and study designs for establishing bioequivalence.
This document discusses modern quality management. It provides an overview of tools and strategies for modern quality management, including quality management forms, ISO templates, key performance indicators, and interview questions. It also discusses the contents of modern quality management, focusing on using quality techniques to identify weak points within complex processes and assess the patient benefits of laboratory testing. Three common quality management tools are also summarized: check sheets for collecting real-time data, control charts for monitoring process stability and variation, and Pareto charts for displaying frequency and cumulative totals of problems or issues.
Prescription event monitoring and record linkage systemVineetha Menon
This document discusses record linkage and its use in pharmacovigilance. Record linkage involves combining records from different data sources that relate to the same individual to create a single longitudinal record. It allows rapid access to a patient's complete medical history across different data sources. This reduces the time needed to study relationships between drug exposure and health outcomes. Challenges include ensuring data quality and completeness when integrating records from various sources.
This document discusses adaptive clinical trials. Adaptive trials allow changes to the trial design based on interim data analysis in order to make the trial more efficient. Key aspects that can be adapted include sample size, treatments, endpoints, and eligibility criteria. Adaptive designs are well-suited for exploratory trials aimed at learning, but confirmatory trials require more prior data and safeguards to ensure the trial's integrity and the validity of its conclusions. The FDA has provided guidance on adaptive designs to ensure patient safety and that adaptive trials meet evidentiary standards for approval.
Real effectiveness medicine pursuing best effectiveness in the ordinary care ...Malmivaara Antti
These slides present a new concept of Real-Effectiveness Medicine (REM), which pursues the best effectiveness of patient care in the real-world setting. In order to reach the goal, four layers of information are needed: 1) expertise or the health care personnel, 2) use of up-to-date scientific evidence, 3) continuous documentation of performance and quality improvement, and 4) benchmarking between providers. The new framework is suggested for clinicians, organizations, policy-makers, and researchers.
This presentation explains the main features of medicines which will be developed and authorised via the adaptive pathways. It provides a definition of real world evidence and the caveats associated with the use and analysis of real world evidence in drug development.
Reasons for conducting clinical trialsJohn Douglas
To explain in simple terms, a clinical trail is a research in human volunteers to answer certain health questions. Carefully conducted clinical trails are the quickest and safest way to discover new treatment
methods that work in people and enhance their health.
This document summarizes a presentation given on the case of high correlation but low reliability in point-of-care monitoring of Coumadin therapy. The presentation describes a situation where a community hospital implemented point-of-care testing (POCT) instruments to monitor patients' PT/INR levels in order to adjust Coumadin dosages during visits. While validation studies showed good correlation between the POCT instruments and the laboratory instruments, clinical staff began experiencing unexpected bleeding events in patients. An investigation revealed that though the instruments showed acceptable validation results, the POCT results were less reliable than indicated, especially near medical decision points. This highlighted that validation studies do not necessarily guarantee reliability in POCT. The presentation aims to provide a risk
The late phase research environment has become more complex due to increased regulatory demands from the FDA and EMA for comprehensive safety data. Sponsors must begin planning late phase studies earlier in the investigative process and work with strategic research partners to effectively plan studies that address therapeutic, regulatory and economic concerns. Failing to take early action can result in costly delays and failure to obtain drug approval. Effective planning is essential to navigating today's complex late phase research landscape.
Educating the Next Generation Pharmacist for Industry. The Panjab University ...Ajaz Hussain
The Panjab University Pharmaceutical Science Oration 2014: Educating the Next Generation Pharmacist for Industry.
“The dream begins with a teacher who believes in you, who tugs and pushes and leads you to the next plateau, sometimes poking you with a sharp stick called ‘truth’.“
Plato, the Republic
What are the most influential ideas, concepts, and developments introduced by ‘pharmaceutical scientists’ over the last 50 years?
How have these ideas/concepts introduced into practice?
How can we improve?
Clinical trials are essential for testing the safety and efficacy of new drugs and medical devices. There are typically 4 phases of clinical trials for drugs, beginning with small safety trials and progressing to large efficacy trials. Medical device trials follow a similar progression but do not use placebos and must compare to existing standards of care. Clinical trials are expensive, with medical device trials costing on average $30,000-$40,000 per enrolled patient. Careful design and management can help minimize costs while still obtaining necessary data.
SDTM Training for personnel with Junior and Intermediate level Clinical Trial Experience. Covers summary of most domains. Salient features include order of domain creation, importance of making programming Data/Metadata Driven, Nature of Clinical Raw Data, Summary of the Clinical Trial process with regards to the data flow to arrive at the Study data to be submitted to regulatory authorities like FDA, Importance of deriving ADAM from SDTM and not directly from raw data, Information has been put together from variety of sources including my own programming work.
Adithyaelearning provides SAS CDM Online Training to the candidates having knowledge in the SAS. Throughout this course the participants will become qualified on the Clinical programming models as well as their usage in field of clinical research. The center areas for the course incorporate data integration, data manipulation, data listings production, figures and tables as per Statistical Examination Plan, as well as generation of reports and graphs. Besides this participants can be trained based on fundamental principles as well as concepts in the statistical methodology as well as clinical trials.
This document provides information about types of experimental studies and clinical trials. It discusses randomized controlled trials as the best way to test new treatments. The key steps in a RCT are described including developing a protocol, obtaining informed consent, randomization of participants, intervention, follow up, and assessment. Sources of bias in clinical trials and different trial designs such as parallel groups and cross-over designs are also summarized.
ich guidelines for clinical trials, scientific approach ppt.pptxJyotshnaDevi4
The document outlines the ICH guidelines for conducting clinical trials. It describes the objectives to promote common understanding and evaluation of foreign clinical trial data. Clinical trials should follow scientific principles and protect subjects. Trials generally proceed through four phases, starting with small healthy volunteer studies (Phase I) to evaluate safety, followed by exploratory efficacy studies (Phase II), then confirmatory efficacy and dosing studies (Phase III), and finally post-marketing studies (Phase IV). Special populations like children, pregnant women, and those with organ impairment require unique consideration. Proper study design, conduct, analysis and reporting are emphasized.
This document summarizes the different types of clinical studies, including clinical trials, cohort studies, and case control studies. It then provides detailed descriptions of clinical trials, including phases of clinical trials from pre-clinical animal studies to post-marketing surveillance. Clinical trials aim to evaluate safety and efficacy of new drugs and are conducted in a phased manner from small healthy volunteer studies to large multicenter studies in patients. Rigorous ethical and scientific standards are followed to ensure safety and quality of clinical research.
This document provides an overview of clinical research and clinical trials. It defines clinical research and clinical trials, discusses the importance of research. It describes the different types and phases of clinical trials, from phase 0 to phase IV. It outlines the key players involved in clinical trials and provides an overview of the clinical trial process from study design to statistical analysis and reporting.
The document discusses clinical research and clinical trials, explaining that clinical trials are important for developing new treatments and furthering medical progress. It covers the different types of clinical trials including treatment, prevention, screening, diagnostic, and quality of life trials. The document also outlines the four phases of clinical trials and the purpose and typical size of participants in each phase.
The document discusses the importance of clinical research for developing new diagnostic methods and treatments through systematic studies on pharmaceutical products in human subjects to evaluate safety, efficacy, and pharmacokinetics. It explains the different types of clinical trials including treatment, prevention, screening, diagnostic, and quality of life trials conducted in four phases to translate basic research findings into improved medical care. The key elements of a clinical trial protocol are also outlined including background information, objectives, methodology, and plans for administration, oversight, and regulation.
Beyond the Horizon: Navigating Late Phase Clinical TrialsRuchi Vahi
Late phase clinical trials are a crucial step in the drug development process, providing valuable information on a drug's safety and efficacy in a larger patient population. Designing and conducting these trials requires careful planning and execution, as well as adherence to ethical and regulatory guidelines.
Visit us: https://mprex.in/project/late-phase-clinical-trials-and-research/
This document discusses key considerations for clinical trial design, size, and study population. It outlines common trial designs like parallel group, crossover, and factorial designs. Appropriate study design and adequate sample size are important to achieve study objectives and answer key questions. Sample size calculations should account for the primary endpoint, expected treatment effect, variability, type I and II errors. Selection of subjects and controls also impacts trial validity. An independent data monitoring committee provides trial oversight.
This white paper discusses four ways that pharmaceutical and biotechnology companies can accelerate their clinical portfolio strategy using advanced analytics and clinical trial data and technology. It provides examples of how visualizing clinical trial data over time, benchmarking trial durations, mapping competitive drug pipelines, and comparing safety profiles across trials can provide insights to help with strategic decision making regarding clinical development.
This document discusses different types of epidemiological studies, with a focus on experimental studies and randomized controlled trials (RCTs). It describes the key features of RCTs, including that they: (1) involve randomly allocating subjects into study and control groups to receive or not receive an intervention, (2) aim to control for confounding factors through randomization, and (3) are considered the gold standard for evaluating interventions due to their ability to minimize bias. The document outlines the basic steps in conducting an RCT, from developing a protocol to randomization, intervention, follow-up, assessment and analysis. It also discusses types of RCTs and their importance in evaluating treatments, prevention, risk factors and more.
The document discusses the four phases of clinical drug trials:
1) Phase I trials test a new drug's safety on a small group of patients and involves monitoring for adverse effects.
2) Phase II trials further evaluate safety and efficacy on a larger group of patients to determine the effective dose.
3) Phase III trials test the drug on hundreds to thousands of patients to confirm effectiveness and monitor long-term safety.
4) Phase IV trials occur after marketing approval to gather additional safety and efficacy data.
The document also outlines principles of research ethics like informed consent, anonymity, and participants' right to withdraw.
The document provides an overview of clinical trials, including:
1) Clinical trials involve studying new drugs, procedures, or therapies on human subjects to test safety and efficacy.
2) Trials are organized into phases from 0 to IV, with Phase 0 involving microdosing and Phase I-III testing in larger groups.
3) Phase IV trials monitor safety after approval and can find rare side effects.
4) Trials must follow ethics guidelines to protect participants and receive oversight from institutional review boards.
The document provides an overview of clinical trials and the drug development process. It discusses the importance of clinical trials in translating basic research into new treatments. There are different types of clinical trials such as treatment, prevention, and diagnostic trials. The drug development process involves drug discovery, pre-clinical animal testing, and 4 phases of clinical trials in humans to test safety, efficacy, and get regulatory approval. Phase 1 trials involve few participants to test safety, while Phase 2 and 3 trials have larger numbers of participants to further evaluate safety and efficacy. Phase 4 trials monitor safety after market approval. Randomization and blinding are important trial design elements to reduce bias.
This document provides an overview of the different phases of clinical trials and drug approval processes. It discusses the key phases of clinical trials (Phase 0-IV), the purpose and objectives of each phase, and common trial types. It also explains the IND, NDA and ANDA processes. The IND allows testing in humans, the NDA seeks approval to market a new drug, and the ANDA provides a streamlined approval path for generic drugs that are equivalent to an existing approved drug. Overall, the document provides a high-level introduction to the clinical trial and drug approval framework.
Similar to Strategies for Considerations Requirement Sample Size in Different Clinical Trials (20)
Anti-Smog Radar Application for VehiclesIJMREMJournal
Smog is regarded as a dangerous situation for vehicles as the visibility of human fails and a person cannot
drive smoothly and safely which can lead to severe accidents and routine disturbances. Hence, “Anti-Smog
Radar Application for Vehicles” is proposed using Internet of Things technology which ensures the smooth flow
of vehicles in smog and prevents accidents in time and cost-efficient manner by detecting and displaying the
front objects with their important information (distance, position, velocity and size) on smart phone used by
authenticated drivers. The radar application controls the hardware system to be deployed on vehicles through
which the user can start, stop and set the hardware in particular direction. The hardware contains NodeMcu
(Microcontroller with built-in Wi-Fi), Ultrasonic sensor and servo motor. The servo is used to detect the
position of front objects and ultrasonic sensor is clipped on servo to detect the objects. For alerts, the objects
are drawn with different colors on application i.e. the red colored objects will be near to the vehicle, the yellow
colored objects will be at some distance from the vehicle and the green colored objects will be far from the
vehicle. Kalman algorithm is used to filter the ultrasonic readings to eliminate the noise. The proposed system
can work in every condition i.e. in day and night.
IoT based Environmental Monitoring and Control SystemIJMREMJournal
IoT plays a major role in collecting the information from the sensing unit enclosing our environment due to
alterations in the climate which led to the significance of environmental monitoring. This Paper presents a
development of real time environmental monitoring and control system by utilizing Node MCU, DHT11 sensor,
ACS712 current sensor, Thing Speak (Open IoT analytics service) and Blynk application. The main task of
monitoring parameters (Humidity, temperature and power consumption) with real time sensors is done by Thing
Speak continuously which has API (Application programming Interface) for gathering sensed data and enabling
users to observe the monitored data in graphs for an interval of every 15 seconds.
This project is also designed to control home devices sitting at any place in the world by utilizing power
efficiently through Blynk application which is used to read data from sensors located in home environment using
smart phone and to turn on/off heating and cooling appliances automatically with respect to room temperature
values.
Analysis and Implementation of Solid-State Relays in Industrial application F...IJMREMJournal
There are many applications and circumstances where switching devices are required for proper operation,
controlling and isolating the high power and low power systems. The most widely used switching devices are
electromechanical relays and solid state relays. In this work, analysis and implementation of solid state relays over
electromechanical relays with respect to instantaneous current supply inindustrial application is conducted and
compared. For this purpose, an experimental setup is arranged for switching operation of electromechanical relays
and solid-state relays.The results of voltage and the current transients are analyzed and compared. It was observed
that there are no transients occurred during switching of solid state relays where as during switching of
electromechanical relay transients observed in volatge and current waveforms. So, it is advisable to use the solid
state relays over electromagnetic relay for safe and smooth operation of the system.
MIM (Mobile Instant Messaging) Classification using Term Frequency-Inverse Do...IJMREMJournal
This document presents a study that aims to classify Mobile Instant Messages (MIMs) from WhatsApp using a Term Frequency-Inverse Document Frequency (TF-IDF) model and Bayesian algorithm. The study collected 417 WhatsApp messages labeled as positive or negative, then preprocessed the data through tokenization, stopword removal, normalization, punctuation removal and stemming. A Bernoulli Naive Bayesian classifier was trained on 75% of the data and tested on the remaining 25%, achieving an accuracy of 81.73% compared to the baseline of 69.23%. The study demonstrated that the proposed hybrid classification approach with preprocessing achieved satisfactory results for sentiment analysis of WhatsApp messages.
Is Lean Management applicable to the hospital and for which results?IJMREMJournal
lean management is a mode of organism inspired by Toyotism; His practice is evident throughout the world and
is one of the most affected institutions, except that the latter is a different profession. There is no shared vision
among the different actors on measuring the performance of the hospital. The activity of the hospital applies to
unique "products": each patient, with its peculiar specificity. The relationship of the workers with the patient is
radically different from the relationship of the worker with his product. That is why the practice of Lean has a
certain specificity in the health field.
Fabrication and Performance Analysis of Solar Tracking System by Using By-Pas...IJMREMJournal
Energy is a burning issue that almost every person experience now a days. Energy demand increases exponentially
since a decade. Due to the global warming and it’s threatening impacts on human life. Therefore, to overcome
such disastrous impacts on the planet, renewable energy resources play vital role now a days. Solar energy is one
of the vastest available renewable energy resources around the globe, but the main issue is its poor efficiency.
Pakistan is facing energy shortage that can be compensated through solar power and the need is to design a project
that maximizes its efficiency. So, the research is mainly focused on improving efficiency of solar panels against
shading loss by using different techniques. In this research, different results will be obtained and compared with
different techniques which are LDR based solar tracking system, by-pass diodes technology and super capacitors.
Fabrication of solar tracker is based on Microcontroller that drives L298N driver to operate stepper motor.
Reactivity Feedback Effect on the Reactor Behaviour during SBLOCA in a 4-loop...IJMREMJournal
The reactivity coefficient is a very important parameter for safety and Stability of reactors operation. To provide
the safety analysis of the reactor, the calculation of changes in reactivity caused by temperature is necessary
because it is related to the reactor operation. The objective is to study the effect of the temperature reactivity
coefficients of fuel and moderator of the PWR core, as well as the moderator density and boron concentration on
fluid density, reactivity, void fraction. peak fuel clad temperature and time to core uncover were found for two
feedback cases. This paper focuses on the effect of the Reactivity feedback, of the 6" (6-inch) Cold Leg
SBLOCA sequences in a 4-loop PWR Westinghouse nuclear power plant with a scram for various feedback,
moderator density coefficient, MDC, moderator temperature coefficient, MTC, the fuel temperature coefficient,
FTC, and boron concentrations. Dragon neutronic code is used for calculating reactivity's coefficient which is
used in RELAP5 thermal hydraulic computer code to simulate the effect of Reactivity feedback during Cold
Leg SBLOCA. The plant nodalization consists of two loops; the first one represents the broken loop and the
second one represents the other three intact loops. In the present analysis two models in RELAP5 code for
computation of the reactivity feedback, separable and tabular models are used. The 6-inch break size was chosen
because the previous work [1], showed that it was the worst size break in a 4-loop PWR Westinghouse. The
results show that the neglecting of the reactivity feed-back effect causes overheating of the clad and that the
importance of the reactivity feed-back on calculating the power (reactivity) which the key parameter that
controls the clad and fuel temperatures to maintain them below their melting point and therefore prevent core
uncover and fuel damage where the fuel temperature, clad temperature and core water level are in the range.
Lyapunov-type inequalities for a fractional q, -difference equation involvin...IJMREMJournal
The document summarizes a research paper that presents new Lyapunov-type inequalities for a fractional boundary value problem involving a fractional difference equation with a p-Laplacian operator. The paper obtains necessary conditions for the existence of nontrivial solutions to the equation. It also presents some applications to eigenvalue problems. Key concepts from fractional calculus such as fractional derivatives and integrals are reviewed. Lemmas establishing uniqueness of solutions to related problems are also presented.
The Policies of Government Intervention as Third-Party for Conflict in Bike-S...IJMREMJournal
This research accesses to the unbalance phenomenon between the rapid development of Sharing bicycle industry
and the good public order. Taking into account the inconsistent goals of bicycle companies and users, the local
government is employed as a third party to mediate the conflict. We establish the conflict model including three
decision makers - Enterprises, Citizens and Government - based on GMCR (Graph Model for Conflict Resolution)
theory, and then find out the equilibrium by means of the decision support system GMCR II. The results show that
the sustainable development of the Sharing bicycle market requires the cooperation and efforts of all the three
parties, the government plays a necessary role to guide the enterprises and the users. We also propose some
management insights on how to provide suggestions for the sharing bicycle companies to improve their
dispatching services, and how to establish and improve relevant laws and regulations to guide citizens to use
shared bicycles in order to achieve mutual benefits
Epidemiological study for Trichomonas Vaginalis for Discrete time model and C...IJMREMJournal
During the period of July until December 2017 Conduct an epidemiological study to investigate the prevalence
of Trichomonas Vaginalis among women who have been consulted for the consultation and emergency of the
maternity and child hospital in Diwaniyah city in Iraq. The number of specimens examined was 857 samples
and the ages ranged between 15-60 years. After the swabs were taken, the direct examination and coloring and
planting on the different food communities to diagnose parasitic Trichomonas vaginalis the incidence of
Trichomonas vaginalis was 129 (17%). Using the mathematical model discrete time model and continuous time
model, it was observed that the highest percentage of infection was in July and the disease began to fade until it
reached the lowest rate in December. Using the mathematical model mentioned above, it was noted that
teaching a significant role in curbing the spread of the disease.
Energy Conservation through Smart Building and Smart Lighting SystemIJMREMJournal
Energy conservation is an extensive topic due to the propagation of electricity demand and challenges globally
and is regarded as one of the most significant issues affects the power system quality, global environment and
consumers. Smart building is a technology that can connect everything to networks or systems to monitor and
control them in various areas such as offices, energy-consuming devices especially in laboratories, security
devices etc. Nevertheless, people's perception about using smart technology for energy saving is still in the mind’s
eye. This means that people discuss about environmental awareness readily. Due to the availability of electricity
and its elemental role, regulating consumers’ behaviours towards power savings can be a challenge. Remarkably,
the gap in today's smart technology design in smart buildings is the compassionate of consumers’ attitudes and
the merging of this perspective into the smart technology. Implementation of PLC based controlling system is a
convenient method to save the power and energy strategy for whole building. Furthermore, prepare a lighting
scheme can results a rapid response in energy conservation. Consequently, PLC Automatic system removes the
human intervention which makes the process smart and energy reduction will gives benefits to the consumers in
terms of reducing the cost of electricity bills. Nonetheless, contemporary buildings’ energy conservation has been
significant solution to cope with the rising electricity necessity.
The Effect of Workplace Relationship toward Job Satisfaction of Divine Word C...IJMREMJournal
The study was conducted to determine workplace relationship between employer and employees and among employees of Divine Word Colleges in Ilocos Sur, Philippines and its effect on the job satisfaction. Literatures and studies were reviewed, and questionnaires were used to gather the data related to workplace relationship and job satisfaction. The respondents of the study are employees of the colleges of Ilocos region which include Ilocos Sur and Ilocos Norte. The study is a descriptive study involving survey and fact-finding inquiry. Weighted mean and Pearson r were used to determine the workplace relationship and its correlation with job satisfaction. The study found that there is a significant correlation between workplace relationship and job satisfaction. Therefore, the study recommends that management need to monitor and improve workplace relationship between employer and employees and among employees and also improve and monitor factors that affect job satisfaction.
Semi-automatic Picture Book Generation based on Story Model and Agent-based S...IJMREMJournal
In the fields of artificial intelligence, automatic narrative generation has attracted considerable interest. Lots of studies on narrative generation have been reported such as novel, comic, and picture book. However, most of those reuse original stories, pictures, and sentences. As a result, there is a problem that generated narratives infringe on copyright. In this paper, we focus on the picture book as the narrative because picture book is a mix of images and language. As a first step of automatic story generation without representation mediums, we propose a novel semi-automatic picture book generation method based on story model and agent-based simulation. The computational experiments are carried out to confirm the effectiveness of the proposed method
Efficiency Evaluation of Thailand Gross Domestic Product Using DEAIJMREMJournal
The goal of this research is to evaluate the efficiency of GDP in Thailand from the past years and provide suggestions for government and policy-makers on ways to manage inputs and improve outputs in the future while enhancing the GDP of Thailand. The paper analyzed the data collected from Office of the National Economic and Social Development of Thailand through a period of 25 years ranging from 1993 to 2017. The results show that the year 2017 was the worst years in terms of efficiency. In order to achieve the research goal, data envelopment analysis (DEA) was used. Theoretically, research has found that evaluation of GDP can be improved by eradicating the negative values of slack movement. In economic terms, the research proposed the promotion of export-led growth, business incubators, and entrepreneurship to boost not only the inputs but also the GPD of the country. In general, the GDP of Thailand is quite efficient. This research can provide strategic advice for Thai Government to improve the Gross Domestic Product thoroughly
Predicting Trade Conflict Outcomes using a Third-Party Intervention ModelIJMREMJournal
As anti-import sentiment and protectionism have been increasing, more papers have focused on using theories to explain or resolve them. However, most research has focused on disputes involving larger nations such that there is not much relatable information for disputes such as the one between South Africa and Zimbabwe. The aim of this paper was to bridge the knowledge gap by using the graph model for conflict resolution and the decision support software GMCRII to simulate possible responses to this regional trade conflict. This thirdparty intervention model will assist in investigating and prescribing a diplomatic solution with fair compromise to resolve the unequal trade problem between Zimbabwe and South Africa without harming the economies of both the countries. This research found that a peaceful resolution of the disagreement could be found by the addition of a third-party to help in the conflict resolution thereby ending the prolonged trade conflict. This undertaking will serve as a template for modelling and predicting an outcome in the event of third-party intervention for future trade disputes involving regional trade partners with emerging or developing economies such as those that exist in Africa
Proposed Framework for Effective Management of End-User Stakeholders’ in Publ...IJMREMJournal
Significant infrastructure such as roads, prisons, schools, rail tracks and train systems, among others are currently developed through the involvement of Public Private Partnership (PPP) arrangements which have been acknowledged internationally in recent time. The poor management of end-user stakeholder during PPP projects in developing nation like Nigeria has been established as one of the major factor affecting the successful growth and development of PPP projects. Due to the paucity in research on end-user stakeholder management on PPP projects in Nigeria, informs this study aim to expose the main strategic factors that can accommodate end-user stakeholder’s management in any PPP road project in Nigeria. The professionals that have worked on the project cum the end-user of the project area were used as targeted respondents for the adopted case study and survey strategies method approach. Thematic analysis was used to analyse the eighteen (18) interviews that were conducted having completed and analysed total number of 282 questionnaires using reliability and factor analysis approach. Seven valid underlying factors were revealed from 28 variables that were left on the questionnaire data with the aid of factor analysis which were used later as factors affecting end-user stakeholders’ management in PPP road project in Nigeria. A proposed framework was created with the seven underlying factors as a template for any successful PPP road project in developing country like Nigeria. These will quench the agitation of enduser stakeholders’ quarrels on PPP toll road projects
Fresh and Hardened Properties of Ground Granulated Blast Furnace Slag Made Co...IJMREMJournal
This research work was carried out on concrete specimens made with different proportion of Ground Granulated Blast Furnace Slag (GGBFS) as a cement substitution in concrete. To accomplish the goal of the research work, overall 75 cubes and 60 cylinders were made. Out of 75 cubes and 60 cylinders, 15 cubes and 12 cylinders were cast for control concrete, and 60 cubes and 48 cylinders were cast by replacing 5,10,15 and 20% of cement with GGBFS. The cubes and cylinder specimens were 100x100x100 mm and 100x200 mm respectively, and mix design was done for 28 Mpa. All specimens were tested at 3. 7, 28 and 90 days of curing ages. The fresh properties such as workability and hardened properties such as compressive and tensile strength of all mixes were determined. Tests results showed that the workability of the concrete mixes made with GGBFS was higher than control mix. As the percentage of GGBFS increased the workability also increased. Hardened properties of concrete mixes made with GGBFS was lower than control concrete at early ages of curing. At the later age, hardened properties of GGBFS made concrete was more than control concrete. Furthermore, water absorption and density of GGBFS made concrete was lower than control concrete.
Design and Evaluation of Open Graded Hot Mix Asphalt Using Cement as A Grout...IJMREMJournal
Road networks ought to be efficiently designed to be safe, speedy and loading sustaining as it has a significant importance in country’s development. For that, pavement should be designed efficiently to exhibit better strength, durability and economical at the same time. Generally, a pavement is classified as Flexible or Rigid. Flexible pavement is opened early to traffic, has good riding quality and ease of maintenance but owing to heavy loading conditions these pavements are more susceptible to wear and tear. On the contrary rigid pavement is load sustaining, durable but having higher construction cost and poor riding quality. World is heading to semirigid pavement which exhibits characteristics of both these pavements. It is the combination of cement concrete and porous asphalt concrete which is achieved by leaving 25% to 30% air voids infused by cement grouts and is known as Semi-rigid pavement.In this research, semi-rigid pavement was designed using ratio of grout of optimum mix was 1:0.55 at water cement ratio by 2% of cement dosage with SP. Study concludes that, Semirigid pavement’s Marshall stability of 7 days was almost 85% of rigid pavement and 28 days compressive strength of semi-rigid pavement was almost 30.5% that of rigid pavement. Besides, it has been ensured that 7 days strength is comparable to 28 days strength of Semi-rigid pavement.
Design of Cold Recycled Emulsified Asphalt Mixtures Using Portland Cement as ...IJMREMJournal
Cold Recycling is getting popularity in research sector and construction industries because it overcomes all the issues of Hot Mix Asphalt of more consumption of natural resources, high production energy, central plant recycling, effect of greenhouse gases and non-feasibility in colder regions. In this research study, a cold recycled mixture is designed and compared in terms of mechanical and volumetric properties with control hot mix asphalt mixture, using 60% RAP (reclaimed asphalt pavement) aggregates and 40 % virgin aggregates to fulfill gradation requirements. Asphalt emulsion for cold recycled mixtures is used as a binder with varying five contents (4.3%, 4.8%, 5.3%, 5.8% and 6.3%). Also, a modified cold recycled mixture is prepared at optimum emulsion content of control cold recycled mixture by partially replacing conventional aggregate mineral filler with three different contents of Portland cement (2%, 3% and 4%) of total dry mass of aggregates. Marshall mix design procedure was adopted to calculate the optimum (bitumen, emulsion and filler content) for control hot mix asphalt, control cold recycled mixture and modified cold recycled mixtures respectively. Mechanical properties of each of these mixtures were compared with each other and it was found that modified cold recycled mixtures were better than controlled cold recycled mixture and comparable in properties to hot mix asphalt mixtures and Optimum filler content of Portland cement for modified cold recycled mixture was found to be at 4%.
Thermodynamic Analysis of Cooling Tower with Air to Air Heat Exchanger for Re...IJMREMJournal
In this paper a thermodynamic analysis of cooling tower with air-to-air heat exchanger is presented. During manual operation of conventional cooling tower, a good quantity of water is evaporated which requires equivalent amount of makeup water for their condensers. So, in this regard, the thermodynamic model of a cooling with an air to air heat exchanger is developed using engineering equation solver (EES) software and then simulated in different climatic conditions of two major cities of Pakistan namely Karachi and Jamshoro through the period of June & December 2017. The results show a significant variation in water vapor recovery with respect to atmospheric conditions mainly humidity and ambient air temperature. Results reveal that the when a cooling tower coupled with air to air heat exchanger maximum amount of water vapors are recovered at Karachi and ranges up to 67% and 62% in Jamshoro during the month of December.
Advanced control scheme of doubly fed induction generator for wind turbine us...IJECEIAES
This paper describes a speed control device for generating electrical energy on an electricity network based on the doubly fed induction generator (DFIG) used for wind power conversion systems. At first, a double-fed induction generator model was constructed. A control law is formulated to govern the flow of energy between the stator of a DFIG and the energy network using three types of controllers: proportional integral (PI), sliding mode controller (SMC) and second order sliding mode controller (SOSMC). Their different results in terms of power reference tracking, reaction to unexpected speed fluctuations, sensitivity to perturbations, and resilience against machine parameter alterations are compared. MATLAB/Simulink was used to conduct the simulations for the preceding study. Multiple simulations have shown very satisfying results, and the investigations demonstrate the efficacy and power-enhancing capabilities of the suggested control system.
TIME DIVISION MULTIPLEXING TECHNIQUE FOR COMMUNICATION SYSTEMHODECEDSIET
Time Division Multiplexing (TDM) is a method of transmitting multiple signals over a single communication channel by dividing the signal into many segments, each having a very short duration of time. These time slots are then allocated to different data streams, allowing multiple signals to share the same transmission medium efficiently. TDM is widely used in telecommunications and data communication systems.
### How TDM Works
1. **Time Slots Allocation**: The core principle of TDM is to assign distinct time slots to each signal. During each time slot, the respective signal is transmitted, and then the process repeats cyclically. For example, if there are four signals to be transmitted, the TDM cycle will divide time into four slots, each assigned to one signal.
2. **Synchronization**: Synchronization is crucial in TDM systems to ensure that the signals are correctly aligned with their respective time slots. Both the transmitter and receiver must be synchronized to avoid any overlap or loss of data. This synchronization is typically maintained by a clock signal that ensures time slots are accurately aligned.
3. **Frame Structure**: TDM data is organized into frames, where each frame consists of a set of time slots. Each frame is repeated at regular intervals, ensuring continuous transmission of data streams. The frame structure helps in managing the data streams and maintaining the synchronization between the transmitter and receiver.
4. **Multiplexer and Demultiplexer**: At the transmitting end, a multiplexer combines multiple input signals into a single composite signal by assigning each signal to a specific time slot. At the receiving end, a demultiplexer separates the composite signal back into individual signals based on their respective time slots.
### Types of TDM
1. **Synchronous TDM**: In synchronous TDM, time slots are pre-assigned to each signal, regardless of whether the signal has data to transmit or not. This can lead to inefficiencies if some time slots remain empty due to the absence of data.
2. **Asynchronous TDM (or Statistical TDM)**: Asynchronous TDM addresses the inefficiencies of synchronous TDM by allocating time slots dynamically based on the presence of data. Time slots are assigned only when there is data to transmit, which optimizes the use of the communication channel.
### Applications of TDM
- **Telecommunications**: TDM is extensively used in telecommunication systems, such as in T1 and E1 lines, where multiple telephone calls are transmitted over a single line by assigning each call to a specific time slot.
- **Digital Audio and Video Broadcasting**: TDM is used in broadcasting systems to transmit multiple audio or video streams over a single channel, ensuring efficient use of bandwidth.
- **Computer Networks**: TDM is used in network protocols and systems to manage the transmission of data from multiple sources over a single network medium.
### Advantages of TDM
- **Efficient Use of Bandwidth**: TDM all
Harnessing WebAssembly for Real-time Stateless Streaming PipelinesChristina Lin
Traditionally, dealing with real-time data pipelines has involved significant overhead, even for straightforward tasks like data transformation or masking. However, in this talk, we’ll venture into the dynamic realm of WebAssembly (WASM) and discover how it can revolutionize the creation of stateless streaming pipelines within a Kafka (Redpanda) broker. These pipelines are adept at managing low-latency, high-data-volume scenarios.
A review on techniques and modelling methodologies used for checking electrom...nooriasukmaningtyas
The proper function of the integrated circuit (IC) in an inhibiting electromagnetic environment has always been a serious concern throughout the decades of revolution in the world of electronics, from disjunct devices to today’s integrated circuit technology, where billions of transistors are combined on a single chip. The automotive industry and smart vehicles in particular, are confronting design issues such as being prone to electromagnetic interference (EMI). Electronic control devices calculate incorrect outputs because of EMI and sensors give misleading values which can prove fatal in case of automotives. In this paper, the authors have non exhaustively tried to review research work concerned with the investigation of EMI in ICs and prediction of this EMI using various modelling methodologies and measurement setups.
DEEP LEARNING FOR SMART GRID INTRUSION DETECTION: A HYBRID CNN-LSTM-BASED MODELgerogepatton
As digital technology becomes more deeply embedded in power systems, protecting the communication
networks of Smart Grids (SG) has emerged as a critical concern. Distributed Network Protocol 3 (DNP3)
represents a multi-tiered application layer protocol extensively utilized in Supervisory Control and Data
Acquisition (SCADA)-based smart grids to facilitate real-time data gathering and control functionalities.
Robust Intrusion Detection Systems (IDS) are necessary for early threat detection and mitigation because
of the interconnection of these networks, which makes them vulnerable to a variety of cyberattacks. To
solve this issue, this paper develops a hybrid Deep Learning (DL) model specifically designed for intrusion
detection in smart grids. The proposed approach is a combination of the Convolutional Neural Network
(CNN) and the Long-Short-Term Memory algorithms (LSTM). We employed a recent intrusion detection
dataset (DNP3), which focuses on unauthorized commands and Denial of Service (DoS) cyberattacks, to
train and test our model. The results of our experiments show that our CNN-LSTM method is much better
at finding smart grid intrusions than other deep learning algorithms used for classification. In addition,
our proposed approach improves accuracy, precision, recall, and F1 score, achieving a high detection
accuracy rate of 99.50%.
Redefining brain tumor segmentation: a cutting-edge convolutional neural netw...IJECEIAES
Medical image analysis has witnessed significant advancements with deep learning techniques. In the domain of brain tumor segmentation, the ability to
precisely delineate tumor boundaries from magnetic resonance imaging (MRI)
scans holds profound implications for diagnosis. This study presents an ensemble convolutional neural network (CNN) with transfer learning, integrating
the state-of-the-art Deeplabv3+ architecture with the ResNet18 backbone. The
model is rigorously trained and evaluated, exhibiting remarkable performance
metrics, including an impressive global accuracy of 99.286%, a high-class accuracy of 82.191%, a mean intersection over union (IoU) of 79.900%, a weighted
IoU of 98.620%, and a Boundary F1 (BF) score of 83.303%. Notably, a detailed comparative analysis with existing methods showcases the superiority of
our proposed model. These findings underscore the model’s competence in precise brain tumor localization, underscoring its potential to revolutionize medical
image analysis and enhance healthcare outcomes. This research paves the way
for future exploration and optimization of advanced CNN models in medical
imaging, emphasizing addressing false positives and resource efficiency.
KuberTENes Birthday Bash Guadalajara - K8sGPT first impressionsVictor Morales
K8sGPT is a tool that analyzes and diagnoses Kubernetes clusters. This presentation was used to share the requirements and dependencies to deploy K8sGPT in a local environment.
Using recycled concrete aggregates (RCA) for pavements is crucial to achieving sustainability. Implementing RCA for new pavement can minimize carbon footprint, conserve natural resources, reduce harmful emissions, and lower life cycle costs. Compared to natural aggregate (NA), RCA pavement has fewer comprehensive studies and sustainability assessments.
Batteries -Introduction – Types of Batteries – discharging and charging of battery - characteristics of battery –battery rating- various tests on battery- – Primary battery: silver button cell- Secondary battery :Ni-Cd battery-modern battery: lithium ion battery-maintenance of batteries-choices of batteries for electric vehicle applications.
Fuel Cells: Introduction- importance and classification of fuel cells - description, principle, components, applications of fuel cells: H2-O2 fuel cell, alkaline fuel cell, molten carbonate fuel cell and direct methanol fuel cells.
The Python for beginners. This is an advance computer language.
Strategies for Considerations Requirement Sample Size in Different Clinical Trials
1. International Journal of Modern Research in Engineering & Management (IJMREM)
||Volume|| 1||Issue|| 8 ||Pages|| 07-21 || August 2018|| ISSN: 2581-4540
www.ijmrem.com IJMREM Page 7
Strategies for Considerations Requirement Sample Size in
Different Clinical Trials
Altaiyb Omer Ahmed*1
– Babiker Gafar Yousif2
-Amani Babiker Mohamed3
-
Salma Mustafa Alnaier4
1,2,3,4
Sudan University of science and technology – department of statistics
-------------------------------------------------------ABSTRACT ---------------------------------------------------
Usually the main problem face any investigation it how to determent a sample size, however, some
considerations required in sample size to conduct the efficacy and make realistic well-researched before began
study. This study aimed to determine the maximum possible sample size at different phases of clinical trials and
attempt to achieve the best accuracy of the results. To achieve that the maximum sample size in different phases
we found that the maximum sample size of phase I was (75) relies on largest response rate 20% and the minimal
clinically important difference (MCID) 15%, and because the participants are healthy often that means 15%
enough to show positive results of the transition to the second phase. for the phase II clinical trials; the
maximum sample size was (388) depend on the error 5% and largest response rate 50% when the response rate
should not be less than 20% according to the design used in this phase. Depend on the endpoint and hazard
ratio in phase III clinical trials when the probability of survival of the treatment group equal to median of the
probability of survival 50% we found that the maximum sample size (4796). For the phase IV the maximum
sample size in different phases of clinical trials does not affect whatever the large of the population size and
remains constant as large as possible size.
KEYWORDS: Sample Size, Survival, Phases, Hazard Ratio, Drugs, Clinical Trials
---------------------------------------------------------------------------------------------------------------------------------------
Date of Submission: Date, 10 February 2018 Date of Accepted: 20 March 2018
---------------------------------------------------------------------------------------------------------------------------------------
I. INTRODUCTION
Clinical trials are scientific investigations that examine and evaluate the safety and efficacy of new drugs or
therapeutic procedures using human subjects. The results that these studies generate are considered to be the
most valued data in the area of evidence-based medicine. Understanding the principles behind clinical trials
enables an appreciation of the validity and reliability of their results. 1 When designing a clinical trial, the
objective is to select a sample of patients with the disease or condition under investigation. Sample size
calculations should be based on the way the data will be analyzed. But, even if more complex methods of
analysis will be used ultimately, it is easier and usually sufficient to estimate the sample size assuming a simpler
method of analysis, such as the t-test or two means or chi-square test of two proportions. Consideration should
be given to the source of the patients, the investigators who are going to recruit them, disease status, and any
ethical issues surrounding participation. A set of carefully defined eligibility criteria is essential. This should
ensure that the study findings have ‘external validity’ or, in other words, are generalizable for the treatment of
future patients with the same disease or condition. In this chapter, we discuss some of the important issues to
consider when selecting patients for clinical trials. The aim of a well-designed clinical trial is to ask an
important question about the effectiveness or safety of a treatment andto provide a reliable answer by
performing statistical analysisand assessing whether an observed treatment difference isdue to chance. The
reliability of the answer is determined bythe sample size of the trial: the larger a trial, the less likelywe are to
miss a real difference between treatments by chance, we review the issues that determinean appropriate sample
size for a randomized controlled trial.Theaim clinical trials and attempt to achieve the best accuracy of the
results the statistical power of a study and a study with inadequate power is unethical unless being conducted as
a safety and feasibility study. However, the calculation of sample size is not an exact science. It is therefore
important to make realistic and well-researched assumptions before choosing an appropriate sample size. This
sample size should account for dropouts, and there should be a consideration for interim analyses to be
performed during the study, which can be used to amend the final sample size.
2. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 8
II. CLINICAL TRIALS
Clinical trials are medical research studies to test whether different treatments are safe and how well they work.
Some trials involve healthy members of the public, and others involve patients who may be offered the option of
taking part in a trial during their care and treatment 2 .
Also Clinical trials define as an experiments or observations done in clinical research
Such prospective biomedical or behavioral research studies on human participants are designed to answer
specific questions about biomedical or behavioral interventions, including new treatments (such as
novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that
warrant further study and comparison. Clinical trials generate data on safety and efficacy 3 . They are
conducted only after they have received health authority/ethics committee approval in the country where
approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial –
their approval does not mean that the therapy is 'safe' or effective, only that the trial may be conducted. it
explore how a treatment reacts in the human body and are designed to ensure a drug is tolerated and effective
before it is licensed by regulatory authorities and made available for use by doctors. Studies vary in their
primary goal or endpoint (i.e. the most important outcome of the trial), the number of patients involved, and the
specifics of the study design. However, all clinical studies conform to a strict set of criteria to protect the
patients involved and to ensure rigorous evaluation of the drug. 4 . Many clinical trials to develop new
interventions are conducted in phases. In the early phases, the new intervention is tested in a small number of
participants to assess safety and effectiveness. If the intervention is promising, it may move to later phases of
testing where the number of participants is increased to collect more information on effectiveness and possible
side effects.
A clinical trial evaluates the effect of a new drug (or device or procedure) on human volunteers. These trials can
be used to evaluate the safety of a new drug in healthy human volunteers, or to assess treatment benefits in
patients with a specific disease. Clinical trials can compare a new drug against existing drugs or against dummy
medications (placebo) or they may not have a comparison arm 85 −
TRIALS OF DRUGS : Some clinical trials involve healthy subjects with no pre-existing medical conditions.
Other clinical trials pertain to patients with specific health conditions who are willing to try an experimental
treatment.Usually pilot experiments are conducted to gain insights for design of the clinical trial to follow.There
are two goals to testing medical treatments: to learn whether they work well enough, called "efficacy" or
"effectiveness"; and to learn whether they are safe enough, called "safety". Neither is an absolute criterion; both
safety and efficacy are evaluated relative to how the treatment is intended to be used, what other treatments are
available, and the severity of the disease or condition. The benefits must outweigh the risks 109 − . For
example, many drugs to treat cancer have severe side effects that would not be acceptable for an over-the-
counter pain medication, yet the cancer drugs have been approved since they are used under a physician's care,
and are used for a life-threatening condition 11 . Compounds, no matter how promising or impassioned the
pleas for use, have to go through a series oftests in animals before they can be tested in humans.Those
considered to lack promise after animal testingdo not come to testing in humans 12 .Typically, the testing in
humans is done in a timeordered sequence, as suggested by the phase labelaffixed to trials as defined below.
However, in truth, adjoining phases overlap in purpose. Hence, the label, at best, serves only as a rough
indicator of the stage of testing, especially when, as is often the case, drugsponsors, at any given point in time,
may have severaltrials under way carrying different phase labels.
PHASES OF CLINICAL TRIALS : The phases of clinical trials are the steps in which scientists do
experiments with a health intervention in an attempt to find enough evidence for a process which would be
useful as a medical treatment. In the case of pharmaceutical study, the phases start with drug design and drug
discovery then proceed on to animal testing. If this is successful, they begin the clinical phase of development
by testing for safety in a few human subjects and expand to test in many study participants to determine if the
treatment is effective. 13 Clinical trials are usually conducted in phases that build on one another. Each phase
is designed to answer certain questions. Knowing the phase of the clinical trial is important because it can give
you some idea about how much is known about the treatment being studied. There are pros and cons to taking
part in each phase of a clinical trial. Four phases of clinical trials and medicine development exist and are
3. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 9
defined below. Each of these definitions is a functional one and the terms are not defined on a strict
chronological basis. An investigational medicine is often evaluated in tow or more phases simultaneously in
different clinical trials. 1714−
PHASE 0 CLINICAL TRIALS : Even though phase 0 studies are done in humans, this type of study isn’t like
the other phases of clinical trials. The purpose of this phase is to help speed up and streamline the drug approval
process. Phase 0 studies are exploratory studies that often use only a few small doses of a new drug in a few
patients. They might test whether the drug reaches the tumor, how the drug acts in the human body, and how
cancer cells in the human body respond to the drug. The patients in these studies might need extra tests such as
biopsies, scans, and blood samples as part of the study process. The biggest difference between phase 0 and the
later phases of clinical trials is that there’s almost no chance the volunteer will benefit by taking part in a phase
0 trial – the benefit will be for other people in the future. Because drug doses are low, there’s also less risk to the
patient in phase 0 studies compared to phase I studies. Phase 0 studies help researchers find out whether the
drugs do what they’re expected to do. If there are problems with the way the drug is absorbed or acts in the
body, this should become clear very quickly in a phase 0 clinical trials. This process may help avoid the delay
and expense of finding out years later in phase II or even phase III clinical trials that the drug doesn’t act as
expected to base on lab studies. Phase 0 studies aren’t used widely, and there are some drugs for which they
wouldn’t be helpful. Phase 0 studies are very small, often with fewer than 15 people, and the drug is given only
for a short time. They’re not a required part of testing a new drug.
PHASE 1 CLINICAL TRIALS : Phase I studies of a new drug are usually the first that involve people. The
main reason for doing it is to find the highest dose of the new treatment that can be given safely without serious
side effects. Although the treatment has been tested in lab and animal studies, the side effects in people can’t
always be predicted. These studies also help to decide on the best way to give the new treatment. Researchers
test an experimental drug or treatment in a small group of people Key points of phase I clinical trials observed
such as: The first few people in the study often get a very low dose of the treatment and are watched very
closely. If there are only minor side effects, the next few participants may get a higher dose. This process
continues until doctors find a dose that’s most likely to work while having an acceptable level of side effects.
Safety is the main concern at this point. Doctors keep a close eye on the people and watch for any serious side
effects. Because of the small numbers of people in phase I studies, rare side effects may not be seen until later.
Placebos are not part of phase I trials. These studies usually include a small number of people (typically up to a
few dozen) and are not designed to find out if the new treatment works against disease. In Overall, phase I trials
are the ones with the most potential risk.
PHASE II CLINICAL TRIALS : If a new treatment is found to be reasonably safe in Phase I clinical trials, it
can then be tested in a phase II clinical trial to find out if it works. The type of benefit or response the doctors
look for depends on the goal of the treatment. It may mean the disease shrinks or disappears. Or it might mean
there’s an extended period of time where the disease doesn’t get any bigger, or there’s a longer time before the
disease comes back. In some studies, the benefit may be an improved quality of life. Many studies look to see if
people getting the new treatment live longer than they would have been expected to without the treatment. Also
Key points of phase II clinical trials must be concentrations: Usually, a group of 25 to 100 patients with the
same type of disease get the new treatment in a phase II study. They’re treated using the dose and method found
to be the safest and most effective in phase I studies. In a phase II clinical trial, all the volunteers usually get the
same dose. But some phase II studies randomly assign participants to different treatment groups. These groups
may get different doses or get the treatment in different ways to see which provides the best balance of safety
and effectiveness. No placebo is used. Phase II studies are often done at major disease centers, but may also be
done in community hospitals or even doctors’ offices. Larger numbers of patients get the treatment in phase II
studies, so there’s a better chance that less common side effects may be seen. If enough patients benefit from the
treatment, and the side effects aren’t too bad, the treatment is allowed to go on to a phase III clinical trial. Along
with watching for responses, the research team keeps looking for any side effects.
Phase IIa: Pilot clinical trials to evaluate efficacy (and safety) in selected populationsof patients with the disease
or condition to be treated, diagnosed, or prevented. Objectives may focus on dose-response, type of patient,
frequency of dosing, ornumerous other characteristics of safety and efficacy. Phase IIb: Well controlled trials to
evaluate efficacy (and safety) in patients with the disease or condition to be treated, diagnosed, or prevented.
These clinical trialsusually represent the most rigorous demonstration of a medicine's efficacy. Sometimes
referred to as pivotal trials. Some Phase II trials are designed as case series, demonstrating a drug's safety and
4. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 10
activity in a selected group of patients. Other Phase II trials are designed as randomized controlled trials, where
some patients receive the drug/device and others receive placebo/standard treatment. Randomized Phase II trials
have far fewer patients than randomized Phase III trials. 18
PHASE III CLINICAL TRIALS : Treatments that have been shown to work in phase II studies usually must
succeed in one more phase of testing before they’re approved for general use. Phase III clinical trials compare
the safety and effectiveness of the new treatment against the current standard treatment. Because doctors do not
yet know which treatment is better, study participants are often picked at random to get either the standard
treatment or the new treatment. When possible, neither the doctor nor the patient knows which of the treatments
the patient is getting. This type of study is called a double-blind study. Randomization and blinding are
discussed in more detail later. Key points of phase III clinical trials: Most phase III clinical trials have a large
number of patients, at least several hundred. These studies are often done in many places across the country (or
even around the world) at the same time. Phase III clinical trials are more likely to be offered by community-
based oncologists. These studies tend to last longer than phase I and II studies. Placebos may be used in some
phase III studies, but they’re never used alone if there’s a treatment available that works. As with other studies,
patients in phase III clinical trials are watched closely for side effects, and treatment is stopped if they’re too
bad.
Phase IIIa: Trials conducted after efficacy of the medicine is demonstrated, but priorto regulatory submission of
a New Drug Application (NDA) or other dossier. These clinical trials are conducted in patient populations for
which the medicine is eventually intended. Phase IIIa clinical trials generate additional data on both safety
and efficacy in relatively large numbers of patients in both controlled and
uncontrolled trials. Clinical trials are also conducted in special groups of patients (e.g., renal failure patients), or
under special conditions dictated by the nature ofthe medicine and disease. These trials often provide much of
the information neededfor the package insert and labeling of the medicine.
Phase IIIb: Clinical trials conducted after regulatory submission of an NDA or other dossier, but prior to the
medicine's approval and launch. These trials maysupplement earlier trials, complete earlier trials, or may be
directed toward newtypes of trials (e.g., quality of life, marketing) or Phase IV evaluations. This is theperiod
between submission and approval of a regulatory dossier for marketing authorization. 19
PHASE IV CLINICAL TRIALS : Drugs approved by food and drug administration (FDA) are often watched
over a long period of time in phase IV studies. Even after testing a new medicine on thousands of people, the
full effects of the treatment may not be known. Some questions may still need to be answered. For example, a
drug may get FDA approval because it was shown to reduce the risk of cancer coming back after treatment. But
does this mean that those who get it are more likely to live longer? Are there rare side effects that haven’t been
seen yet, or side effects that only show up after a person has taken the drug for a long time? These types of
questions may take many more years to answer, and are often addressed in phase IV clinical trials. This is
typically the safest type of clinical trial because the treatment has already been studied a lot and might have
already been used in many people. Phase IV studies look at safety over time. These studies may also look at
other aspects of the treatment, such as quality of life or cost effectiveness 20 . Studies or trials conducted after
a medicine is marketed to provide additional details about the medicine's efficacy or safety profile. Different
formulations, dosages, durations of treatment, medicine interactions, and other medicine comparisons may be
evaluated. New age groups, races, and other types of patients can be studied. Detection and definition of
previously unknown or inadequately quantified adverse reactions and related risk factors are an important aspect
of many Phase IV studies. If a marketed medicine is to be evaluated for another (i.e., new) indication, then those
clinical trials are considered Phase II clinical trials. The term post-marketing surveillance is frequently used to
describe those clinical studies in Phase IV (i.e., the period following marketing) that are primarily observational
or non-experimental in nature, to distinguish them from well controlled Phase IV clinical trials or marketing
studies 21 . You can get the drugs used in a phase IV trial without enrolling in a study. And the care you would
get in a phase IV study is very much like the care you could expect if you were to get the treatment outside of a
clinical trial. But in phase IV studies you’re helping researchers learn more about the treatment and doing a
service to future patients.
5. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 11
III. GENERAL CONSIDERATIONS
Calculation of sample size requires precise specification of the primary hypothesis of the study and the method
of analysis. In classical statistical terms, one selects a null hypothesis a long with its associated type I error rate,
an alternative hypothesis a long with its associated statistical power, and the test statistic one intends to use to
distinguish between the two hypotheses. Sample size calculation becomes an exercise in determining the
number of participants required to achieve simultaneously the desired type I error rate and the desired power.
For test statistics with well known distributional properties, one may use a standard formula for sample size.
Controlled trials often involve deviations from assumptions such that the test statistic has more complicated
behavior than a simple formula allows. Loss to follow-up, incomplete compliance with therapy, heterogeneity of
the patient population, or variability inconcomitant treatment among centers of a multicenter trialmay require
modifications of standard formulas 22 . In some situations, however, the anticipated complexities of a given
trial may render all available formulas inadequate. In such cases, the investigator can simulate the trial using an
adequate numberof randomly generated outcomes and select the sample size on the basis of those computer
simulations.Complicated studies often benefit from a three-step strategy in calculating sample size. First, one
may use a simple formula to approximate the necessary size over a range of parameters of interest under a set of
ideal assumptions (e.g., no loss to follow-up, full compliance, homogeneity of treatment effect). This calculation
allows a rough projection of the resources necessary. Having established the feasibilityof the trial and having
further discussed the likely deviations from assumptions, one may then use more refined calculations. Finally, a
trial that includes highly specialized features may benefit from simulation for selection of a more appropriate
size
IV. GEHAN'S TWO – STAGE DESIGN
Discarding ineffective treatments early: If it is unlikely that a treatment will achieve some minimal level of
response or efficacy, we may want to stop the trial as early as possible. For example, suppose that a 20%
response rate is the lowest response rate that is considered acceptable for a new treatment. If we get no
responses in n patients, with n sufficiently large, then we may feel confident that the treatment is ineffective.
Statistically, this may be posed as follows: How large must n be so that if there are 0 responses among
n patients we are relatively confident that the response rate is not 20% or better? If X ∼b(n, π), and if π ≥ .2,
then Pπ(X = 0) Choose n so that .8n
= .05 or n ln(.8) = ln(.05). This
leads to n ≈ 14 (rounding up). Thus, with 14 patients, it is unlikely (≤ .05) that no one would respond if the true
response rate was greater than 20%. Thus 0 patients responding among 14 might be used as evidence to stop the
phase II trial and declare the treatment a failure 23 . This is the logic behind Gehan’s two-stage design. Gehan
suggested the following strategy:
If the minimal acceptable response rate is π0, then choose the first stage with n0 patients such that (1 - π0)n0
=
.05; n0 =
If at least one response is observed in first 14 patients then a second stage of accrual is carried out to obtain an
estimate of the response rate. The number of patients to accrue in the second stage depends on the number of
response observed in the first stage and the precision desired for the final estimate of response rate. If the first
stage consist 14 patients the second stage will consist of:
Between 1 and 11 patients, if a standard error of 10% is desired
Between 45 and 86 patients, if a standard error of 5% is desired
A problem of Gehan’s design is it may allow a very poor drug to move to the second stage. for example, if a
drug has a response rate of only 5% , there exists at 51% chance of obtaining at least one response among the
first 14 patients consequently ,the first stage 14 patients would not effectively screen inactive drugs.
Assume that X is random variable follow the binomial distribution Bin ( )
Let response rate 20%
=
=
6. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 12
Then the sample size is:
)1(
)1log(
)log(
−
=n
Stage1: To determine the sample size in stage 1 used the following formula
)2(
)1log(
)1log(
1
−
−
=
n
n
Where
Response rate
Stage2: The sample size in stage2 calculate with 24
)3(
)1(
2
2
2
−
=
Z
n
Where
Minimal clinical different
STRATEGIES TO OBTAIN QUALITY SAMPLE
1- Focus your study. Ensure that the research question is feasible and the study answers a question with clear
variables.
2- Find a representative sample. Determine the essential inclusion and exclusion criteria for the study
population such that findings can accurately generalize or specify results to the target group. 25
3- Determine a recruitment strategy. Specify a plan to identify and enroll study participants. This may involve
screening or establishing criteria for number, location, and sampling method.
4- Consult with the community to identify and recruit potential participants. Examine existing infrastructure to
find venues of contacting appropriate samples.
5- To avoid selection bias, it is also necessary to recruit an appropriate comparison group.
6- Do not give up after the first attempt to recruit a potential participant. Follow-up using various
communication strategies, including personal, written, or electronic messaging. “The significance of
personal contact should not be underestimated. 26
7- Allow for flexibility in the process. If current recruitment strategies are resulting in “inadequate enrollment”
or modifications are made in criteria of participants, the solution may be to alter the sampling plan.
SAMPLE SIZE CALCULATION FOR TESTING A HYPOTHESIS
In this kind of research design researcher wants to see the effect of an intervention. Suppose a researcher want to
see the effect of an antihypertensive drug so he will select two groups, one group will be given antihypertensive
drug and another group will be give placebo. After giving these drugs for a fixed time period blood pressure of
both groups will be measured and mean blood pressure of both groups will be compared to see if difference is
significant or not. Complex formulae are used for this type of studies and we want to advise readers to use
statistical software for calculation of exact sample size. The procedure for calculation of sample size in clinical
trials/intervention studies involving two groups is mentioned here. In the case of only two groups method of
calculation is mentioned here but if design involves more than two groups then statistical software like G Power
should be used for sample size calculation. But understanding of various prerequisites which are needed for
sample size calculation is very important 2827−
BASIC REQUIREMENT FOR ESTIMATION OF SAMPLE SIZE IN CT
Following are the basic considerations for estimating sample size for a CT
Study Design : In CT, different statistical study designs are available to achieve objectives. Typical designs that
may be employed are parallel group design; crossover design etc.For sample size estimation study design should
be explicitly defined in the objective of the trial. A cross over design will have different approach and formula
for sample size estimation as compared to parallel group design.
7. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 13
Hypothesis Testing :This is another critical parameter needed for sample size estimation, which describes aim
of a CT. The aim can be equality, non-inferiority, superiority or equivalence.Equality and equivalence trials are
two-sided trials where as non-inferiority and superiority trials are one-sided trials.Superiority or non-inferiority
trials can be conducted only if there is prior information available about the test drug on a specific end point.
Primary Study End Point : The sample size calculation depends on primary end point of a CT. The description
of primary study end point should cover whether it is discrete or continuous or time-to-event. Sample size is
estimated differently for each of these end points. Sample size is adjusted if primary end point involves multiple
comparisons.
Expected Response Test vs. Control :The information about expected response is usually obtained from
previous trials done on the test drug. If this information is not available, it could be obtained from previous
published literature. The important information required is:
a. Response expected with test drug (mean expected score / proportion of subjects achieving success.)
b. Response expected with control drug (mean expected score / proportion of subjects achieving success.)
c. Variability (standard deviation.)
Clinical Important/Meaningful Difference/Margin : This is one of most critical and one of most challenging
parameters. The challenge here is to define a difference between test and reference which can be considered
clinically meaningful. To put it in plain English, this is the difference which will make your family doctor to
give you new medication over and above the existing gold standard which he is prescribing for last 10 – 20
years. This threshold figure is at times not easily available and should be decided based on clinical judgment.
Level of Significance : This is typically assumed as 5% or lesser. Type I error is inversely proportional to
sample size.
Power : As per guideline power should not be less that 80%. Type II error is directly proportional to sample
size. 3129−
Margin of error: The margin of error is the level of precision you require. This is the plus or minus number
that is often reported with an estimated proportion and is also called the confidence interval. It is the range in
which the true population proportion is estimated to be and is often expressed in percentage points (e.g., ±2%).
Note that the actual precision achieved after you collect your data will be more or less than this target amount,
because it will be based on the proportion estimated from the data and not your expected sample proportion.
Confidence level : The confidence level is the probability that the margin of error contains the true proportion.
If the study was repeated and the range calculated each time, you would expect the true value to lie within these
ranges on 95% of occasions. The higher the confidence level the more certain you can be that the interval
contains the true proportion.
Population size: This is the total number of distinct individuals in your population. In this formula we use a
finite population correction to account for sampling from populations that are small. If your population is large,
but you don’t know how large you can conservatively use 100,000. The sample size doesn’t change much for
populations larger than 100,000.
Sample proportion : The sample proportion is what you expect the results to be. This can often be determined
by using the results from a previous survey, or by running a small pilot study. If you are unsure, use 50%, this is
conservative and gives the largest sample size. Note that this sample size calculation uses the Normal
approximation to the Binomial distribution. If, the sample proportion is close to 0 or 1 then this approximation
is not valid and you need to consider an alternative sample size calculation method. Any major mistake in the
sample size calculation will affect the power and value of a study. “Common sample size mistakes include not
performing any calculations, making unrealistic assumptions, failing to account for potential losses during the
study and failing to investigate sample size over a range of assumptions. Reasons for inadequately sized studies
that do not achieve statistical significance include failing to perform sample size calculations, selecting sample
8. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 14
size based on convenience, failing to secure sufficient funding for the project, and not using the available
funding efficiently 32 .
THE END POINT: A clinical trial end point is defined as a measure that allow us to decide whether the null
hypothesis of a clinical trial should be accepted or rejected .in a clinical trial, the null hypothesis states that there
is no statistically significant difference between two treatments or strategies being compared with respect to the
endpoint measure chosen an endpoint can be composed of a single outcome measure –such as death due to the
disease –or a combination of outcome measure, such as death or hospitalization due to the disease. Clinical trial
endpoint can be classified as primary or secondary endpoints. Primary endpoint measure outcome that will
answer the primary (or most important) question being asked by a trial ,such as whether a new treatment is
better at preventing the disease –related death than the standard therapy. in this case ,the primary endpoint
would be based on the occurrence of disease –related deaths during the duration of the trial .Secondary
endpoints ask other questions about the same study; for example , whether there is also a reduction in disease
measures other than death.Occasionally, secondary endpoints are as important as the primary endpoints ,in
which case they are considered to be co-primary endpoints. When secondary endpoint is also important then the
trial must be sufficiently powered to detect a difference in both endpoints, and expert statistical and design
advice might be needed 33 .
SURVIVAL ANALYSIS : In many clinical trials, the outcome is not just whether an event occurs, but also the
time it takes for the event to occur. For example, in a cancer study comparing the relative merits of surgery and
chemotherapy treatments, the outcome measured could be the time from the start of therapy to the death of the
subject. In this case the event of interest is death, but in other situations it might be the end of a period spent in
remission from cancer spread, relief of symptoms, or a further admission to hospital. These types of data are
generally referred to as time-to-event data or survival data, even when the endpoint or the event being studied is
something other than the death of a subject. The term survival analysis encompasses the methods and models
for analyzing such data representing timefree from events of interest.
V. BASIC CONCEPTS IN SURVIVAL ANALYSIS
CENSORING: In survival analysis, not all subjects are involved in the study for the same length of time due to
censoring. This term denotes when information on the outcome status of a subject stops being available. This
can be because the patient is lost to follow-up (eg, they have moved away) or stops participating in the study, or
because the end of the study observation period is reached without the subject having an event. Censoring is a
nearly universal feature of survival data.
SURVIVAL FUNCTION AND HAZARD FUNCTION : In survival analysis, two functions are of central
interest, namely survival function and hazard function. The survival function, S(t), is the probability that the
survival time of an individual is greater than or equal to time t. Since S(t) is the probability of surviving (or
remaining event-free) to time t, 1 – S(t) is the probability of experiencing an event by time t. Put simply, as t
gets larger, the probability of an event increases and therefore S(t) decreases. Plotting a graphof probability
against time produces a survival curve, which is a useful component in the analysis of such data. Since S(t) is a
probability, its value must be ≥0 but ≤1.When t = 0, S(0) = 1, indicating that all patients are event-free at the
start of study. Within these restrictions, the S(t) curve can have a wide variety of shapes.The hazard function,
h(t), represents the instantaneous event rate at time t for an individual surviving to time t and, in the case of the
pancreatic cancer trial, it represents the instantaneous death rate. With regard to numerical magnitude, the
hazard is a quantity that has the form of ‘number of events per time. For this reason, the hazard is sometimes
interpreted as an incidence rate. To interpret the value of the hazard, we must know the unit in which time is
measured. Assume we plan a RCT aiming at comparing a new treatment (drug) with an old one (control). Such a
comparison can be made in terms of the hazard ratio or some function of this. Let d stand for the drug and c for
control
In the sequel we describe the sample size required to demonstrate that the drug is better than the control
treatment. This will be made under some assumptions in two steps
9. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 15
Step 1: specify the number of events needed
In what follows we will use the notation below to give a formula specifying the number of events needed to
have a certain asymptotic power in many different cases like.The log-rank test – the score test – parametric tests
based on the exponential distribution – etc.
)4(
)(
2
2
pq
ZC
d
power+
=
Where
the proportion of individual receiving the new drug
the upper quintile of the standard normal distribution
It is not clear how d should estimate. The difficulty lies in the fact that this depends on the exact situation at
hand.
Step 2: specify the number of patients needed to obtain the “the right” number of events.
In what follows we consider how we can specify the number of patients needed to get the “right” number of
events needed to have a certain asymptotic power. In general this will depend on
1-The length of the recruitment period T
2-The recruitment rate R
3- The follow up time F
4-The survival function for the control group
d = 2N x P(event) )2N => d/P(event)
P(event) is a function of the length of total follow-up at time of analysis and the average hazard rate.
In clinical research an end point is often the time to the occurrence of some particular event, such as the death of
patient. These types of data known as survival data. In this section the outcome variable is a time-to-event, for
example when (people are followed until death). In practice, not everyone can be observed until death; some
people will die during the study, while others can be followed until the end of the study period. If these
individuals are still alive at the end of the study; we call their observed follow-up times ‘censored’. Thus the
length of follow-up may vary between individuals and the outcome is dichotomous (event ‘yes’ or ‘no’) 34 . In
survival analysis, two function are of central interest, namely survival functions S(t) and hazard function
h(t). The survival function is the probability that the survival time of an individual is greater than or equal to
time t. the hazard function represent the instantaneous event (death) rate at time t for an individual’s surviving to
time t. To compare two groups of individuals with respect to their follow-up times on two different treatments
(for example a control treatment C and an experimental treatment E), a log-rank test is used. The power of the
log-rank test depends on the total number of events in the study, rather than on the number of individuals
enrolled in the study. Therefore sample size and study duration are determined in two steps. First the number of
events d is estimated as a function of the type I error α, the type II error β (or the power 1-β) and the treatment
effect δ0. The treatment effect δ0 is characterized by the ratio of the hazard rates (i.e. the risks of the occurrence
of the event in the two groups). It is assumed that this hazard ratio does not change with follow-up
time 4135− . The total number of events can be determined by:
)5()()
1
1
(
0
0
ZZd +
−
+
=
10. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 16
Where is equal to the hazard ratio (HR)
)6(
)log(
)log(
0
c
e
P
P
=
the estimated survival probability in the control group
the estimated survival probability in experimental group after a certain follow-up time T.
Next the necessary total number of patients' n can be determined based on the estimated number of events d and
the estimated survival probabilities in the two treatment groups:
)7(
2
2
ec PP
d
n
−−
=
In the other hand when we want to estimate the sample size to compare two responses rate we should use the
formulae as below:
( ) ( )
)8(
)(
))1(1(
021
2211
2
−−
−+−+
=
ZZ
n
SAMPLE SIZE TO ESTIMATE A PROPORTION : When one wants to investigate the presence of disease,
we are dealing with a presence/absence (binomial) situation because each selected element is either infected or
not infected 4642− . One property of the Binomial distribution is that the variance equals p * (1 - p), where p
is expressed as a proportion (or it is p * (100 - p), when p is expressed as a percentage). Of course, the standard
deviation is the square root of p * (1 -p). We can then use the following formula to determine the samples size.
)9(
ˆˆ)1(ˆ
ˆˆ
ˆ
ˆˆ
2
2
2/1
2
2/1
QPZNE
QPNZ
E
QPZ
n
+−
= −−
n = estimated sample size for the study.
Z1-α/2 = value of Z which provides α/2 in each tail of normal curve
Pˆ = the best guess of the prevalence of the disease in the population.
Qˆ = 1− Pˆ
E = allowable error or required precision.
N = population size. If the population size is large, this is irrelevant (equivalent to sampling with replacement).
A property of the variance of a proportion is that it is symmetric around its maximum at p = 0.5 (or 50%).
Hence, the sample size is maximal when p is estimated to be 50%, and this value should be used when there is
no idea of the actual proportion. Be careful with the value you select for E, especially at low or high prevalence.
SAMPLE SIZE TO ESTIMATE DIFFERENCES BETWEEN PROPORTIONS : Suppose you want to
compare two antibiotics. Two groups of animals are infected with an appropriate pathogen and the percentages
of recovery in both groups are compared. How many animals should be included in each group? The following
formula can be used 47 :
)10(
2
2
2
12/1
ce
ccee
PP
QPQPZQPZ
n
−
++
=
−
n = estimated sample size for each of the exposed and unexposed groups.
Z1-α/2 = value of Z which provides α/2 in each tail of normal curve.
11. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 17
Z1-β = value of Z which provides β in the tail of normal curve. β specifies the probability of declaring a
difference to be statistically no significant when there is a real difference in the population.
Pe = estimate of response rate in exposed group or exposure rate in cases.
Pc = estimate of response rate in unexposed group or exposure rate in control.
P = (Pe + Pc) / 2
PQ −=1
SAMPLE SIZE TO DETECT A DISEASE IN A POPULATION : Suppose one is interested in the
percentage of farms that are infected with a pathogen X (prevalence based on whether or not the pathogen is
present at a farm). A farm is considered to be infected when at least one of its animals is infected. First the
appropriate number of farms as units of concern is randomly chosen and secondly the status of the farm
(infected or not) is determined. The proportion of infected animals per farm is not of major interest. Ideally, we
would screen all the animals on a farm, but often this is not necessary. Suppose that it is known that if the
disease is present, about 50% of the animals are likely to be positive. By sampling one animal you have a 50%
probability of correctly concluding that a truly positive farm is positive. In general, one aims at a higher
probability to classify a positive farm correctly (e.g., 95%). By selecting 2 animals, the probability is increased
up to 75% (25% of drawings show two negatives), 3 animals yield 87.5%, 4 animals 93.75% and 5 animals
96.875%. Thus, between 4 and 5 animals should be sampled to detect positive farms with a probability of 95%,
if 50% of the animals are truly diseased. The calculations can be put into a general formula 48 :
)11()
2
)1(
(*))1(1(
1
−
−−−=
d
Npn d
n = sample size
p = probability of finding at least one case ( confidence level, e.g., 0.95)
d = number of (detectable) cases in the population
N = population size
If the test that is used to evaluate the status of the animals is not 100% sensitive, d is equal to the number of
diseased or infected animals multiplied by the sensitivity of the test. It is assumed that no false-positives are
present or that they are ruled out by confirmatory tests.
SAMPLE SIZE FORMULA TO ESTIMATE A MEAN
To calculate sample sizes for a mean obtained from a Normal distribution, we need to estimate both the mean
and its standard deviation (S). Secondly, we need to define an interval L, indicating that with a probability of (1
- α)% the true population mean will be within the interval of the sample mean ± L. This interval is therefore an
indication of the precision of the estimate. Thirdly, we have to decide on (1 - α). There is no general rule for this
decision, but 95 are commonly used. From this we can determine the corresponding number of units (Z) of S.
For example, if (1 - α)= 95 then the significance level is 5% and Z0.05 = 1.96. This value indicates that that 95%
of all the observations will fall within the interval: mean ± 1.96*S / √n. The confidence interval (CI) for a mean,
obtained by drawing elements from a Normal distribution, can be written as:
)12(
*2/1
n
SZ
XCI −
=
If the part after the ± sign is denoted as E, n is then calculated as:
)13(
ˆ*
2
22
2/1
E
SZ
n −
=
n = sample size.
Z1-α/2 = value of Z which provides α/2 in each tail of normal curve.
S ˆ = estimate of standard deviation in the population.
E = allowable error or required precision.
SAMPLE SIZE TO ESTIMATE DIFFERENCES BETWEEN MEANS : Sometimes an investigator is
interested in differences between groups of animals. Now we can perform a one-tailed test. This has an impact
on the value of Z1-α: the one-sided value of Z0.05 is equal to the two-sided Z0.10. In order to make the sample size
calculation we need: an estimation of the difference between both groups Xe − Xc = δ the standard deviation of
the trait, the significance level α, the power of the test, i.e., the probability (1-β) of obtaining a significant result
if the true, difference equals Xe − Xc . The sample size formula is written as:
12. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 18
( )
( )
)14(
*
*2
2
12/1
−
+
=
−−
ce XX
SZZ
n
n = estimated sample size for each of the exposed and unexposed groups.
Z1-α/2 = value of Z which provides α/2 in each tail of normal curve.
Z1-β = value of Z which provides β in the tail of normal curve. β specifies the probability of declaring a
difference to be statistically no significant when there is a real difference in the population.
S = estimate of standard deviation common to both exposed and unexposed groups.
eX = estimate of mean outcome in exposed group or cases.
cX = estimate of mean outcome in unexposed group or control.
The constant, 2, in the formula arises from the assumption that the S is equal in both groups. The calculated
sample size is the number of individuals per group. 49
VI. CONCLUSION
Determining the sample size usually depends mainly on the quality and purpose of study, some assumptions
required conducting the whole sample such as type I and type II error also the power of test and some
considerations, and a study with inadequate power is unethical unless being conducted as a safety and feasibility
study. It should be done at the time of planning a study, based on the type of the research question and study
design it is therefore important to make realistic and well-researched assumptions before choosing an
appropriate sample size. Clinical trials are very important issue in medical fields specially in the early stage
which need small group of people to assess safety by looking for other any side effects, and later stage involve
large numbers of people to take part and it is depends on the differences between the effects of two treatments
whether large or small. So large numbers of people are needed to find out reliably whether one treatment is
better than another. Statisticians give expert guidance to help the researchers make sure a trial includes enough
people to give reliable results. And not like other fields such as psychological or educational programmers
which needed to assessment of investigator to how determinant a sample size. Finally, can say that the sample
size calculations are only guidelines to how many units should be investigated. It is not a strict number as the
assumptions underlying the calculations will almost never exactly mirror the true values.
REFRENCES
1. Duolao Wang and Ameet Bakhai, - clinical trails a practical guide to design, analysis, and reporting.
Remedica London, 2006
2. National institute for health research- understanding clinical trials version 2 2010 UK
3. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving
Human Subjects. Available from: www.wma.net/e/policy/b3.htm. Accessed May 6, 2005
4. F. Hoffmann-La Roche Ltd GPS Public Affairs 4070, Basel, Switzerland 2013
5. https://www.australianclinicaltrials.gov.au/what-clinical-trial/phases-clinical-trials
6. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving
Human Subjects. Available from: www.wma.net/e/policy/b3.htm. Accessed May 6, 2005.
7. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized
trials: explanation and elaboration. Ann Intern Med 2001;134:663–94.
Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving
the quality of reports of parallel-group randomized clinical trials. Lancet 2001;357:1191–4
8. Jump up^ FDA Page last updated 25 April 2014 FDA's Drug Review Process: Continued
9. Jump up^ PhRMA. February 2007 Drug Discovery and Development
10. Jump up^ Merck Manual. Last full review/revision October 2013 by Daniel A. Hussar, PhD Overview of
Over-the-Counter Drugs
11. Glaucoma Laser Trial Research Group (1991). The Glaucoma Laser Trial (GLT): 3. Design and methods,
Controlled Clinical Trials 12, 504–524.
12. Duolao, W & Dorothea N & Ameet B. Clinical Trials -A Practical Guide to Design, Analysis, and
Reporting Published by Remedica, London WC1A 1NU, UK, Chicago, IL 60606, USA – 2006, 3-12
13. Pocock SJ. Clinical Trials: A Practical Approach. New York: John Wiley & Sons, 1983.
14. Chow SC, Liu JP. Design and Analysis of Clinical Trials: Concept and Methodologies. New York: John
Wiley & Sons, 1998.
13. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 19
15. Friedman LM, Furberg CD, Demets D. Fundamentals of Clinical Trials, 3rd edition. New York:
Springer-Verlag, 1998.
16. Matthews JNS. An Introduction to Randomized Controlled Clinical Trials. London: Arnold, 2000.
17. 1-^ Jump up to:a b c d e f g h i j k DeMets, D.,Friedman, L., and Furberg, C. (2010). Fundamentals of
Clinical Trials (4th ed.). Springer. ISBN 978-1-4419-1585-6.
18. Spilker, Bert. Guide to Clinical Trials, Raven Press, 1984. Page XXii-Xxiii.
19. http://www.clinicaltrials.gov/ct2/info/understand
20. http://www.dddmag.com/the-cost-of-clinical-trials.aspx
21. Janet wittes 2002, Sample Size Calculations for Randomized Controlled trails, johns Hopkins Bloomberg
school of public health VOL 24, NO 1, USA, 39 -53
22. Gehan EA, Schneiderman MA: Historical and methodological developments in clinical trials at the
national cancer institute’s .Stat .Med 9:871-1990.
23. Daowen Zhang Department of Statistics North Carolina State University c 2009 by Anastasios A. Tsiatis
and Daowen Zhang
24. Scott smith, Determining Sample Size: How to Ensure You Get the Correct Sample Size 2013
25. Patel, M., Doku, V., and Tennakoon, L. “Challenges in recruitment of research participants.”Advances in
Psychiatric Treatment. 9. (2003) Accessed on 22 June 2011.
26. Kasiulevicius V, Sapoka V, Filipaviciute R. Sample size calculation in epidemiological
studies. Gerontology. 2006;7:225–31.
27. Cai J, Zeng D. Sample size/power calculation for case-cohort studies. Biometrics. 2004;60:1015–
24. [PubMed]
28. Shein-Shung C, Jun S, Hansheng W. Sample Size Calculation in Clinical Trial. New York: Marcel
Dekker Inc; 2003. Chapter 1, page 11, section 1.2.3.
29. ICH Topic E 9, Statistical Principal for Clinical Trials Step 4, Consensus guideline, 05Feb1998 Note for
Guidance On Statistical Principles For Clinical Trial. Available viahttp://www.ich.org .
30. Tushar Vijay Sakpal, (2010) "Sample Size Estimation in Clinical Trial" Perspect Clin Res,
PMCID: PMC3148614 PP 67-69
31. Fosgate GT. Practical sample size calculations for surveillance and diagnostic investigations. J Vet Diagn
Invest. 2009;21:3–14. [PubMed]
32. Temple RJ.A regulatory authority’s opinion about Surrogate endpoint. In: Nimmo WS, Tuker GT, editor
.clinical Measurement in Drug Evaluation. New York: John Wiley and sons, 1995: 3-22. 2) Fleming TR,
DeMets DL .Surrgate endpoint in clinical trials :are we
33. Ziad Taib lectures note in Biostatistics Astra Zeneca, Chalmers University of technology- Goteborg
March 12, 2008
34. Ingeborg van der Tweel, Sample size determination Intern report Julius Center for Health Sciences and
Primary Care, October, 2006
35. Collett D. Modelling Survival Data in Medical Research, 2nd edition. London: Chapman and Hall, 2003.
Cox DR, Oakes D. Analysis of Survival Data. London: Chapman and Hall, 1984.
Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good
practice and pitfalls. Lancet 2002;359:1686–9.
36. Bland JM, Altman DG. Survival probabilities (the Kaplan–Meier method).BMJ 1998;317:1572.
Kirkwood B, Sterne J. Essential Medical Statistics, 2nd edition. Oxford: Blackwell Publishing, 2003.
http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSiz
37. Todd S et al., Interim analyses and sequential designs in phase III studies. Br J ClinPharmacol, 2001, 51:
394-399.
38. Donner A. Approaches to sample size estimation in the design of clinical trials- a review. Statistics in
Medicine, 1984, 9: 199-214
39. Friedman LM, CD Furberg, DL DeMets. Fundamentals of clinical trials (3d ed.). Springer Verlag, New
York (1998).
40. Greenland S. Power, sample size and smallest detectable effect determination for
multivariate studies. Statistics in Medicine, 1985, 4: 117-127.
41. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Contr Clin
Trials, 1981, 2: 93-113.
42. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd Ed. New York: Wiley; 1981.
43. Cannon, R.M. and Roe, R.T. (1982). Livestock Disease Surveys. A Field Manual for Veterinarians.
Bureau of Resource Science, Department of Primary Industry. Aust. Gov. Publ. Serv. Canberra, 35.
44. Ludbrook J. Interim analyses of data as they accumulate in laboratory experimentation. BMC Medical
research Methodology, 2003, 3: 15.
14. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 20
FIGURES AND TABLES
The numeric result and plots : To determinant the best sample size for each formula; firstly we determine the
elements such as phase clinical trial, type I error, type II error and the margin of error, and after that we must
applied in varies formula to get the sample size. Each of them respect to limited situation and according to
formula mentioned previously.
Table (1): Samples size of phase 1 clinical trial if type I error =5%, type II error =10% with = 15%
Margin of error
0.05 0.10 36 0.16
0.05 0.15 30 0.18
0.05 0.20 24 0.21
0.10 0.15 57 0.12
0.10 0.20 37 0.16
0.15 0.20 75 0.10
Figure (1)
Figure1. Sample size and error of phase I
Table (2): Sample size in phase II clinical trials
Sample Stage 1 Stage 2 Total Power
1 0.2 14 246 260 0.05
2 0.3 8 323 331 0.845
3 0.4 6 369 375 0.9998
4 0.5 4 384 388 0.9999
15. Strategies for Considerations Requirement Sample Size…
www.ijmrem.com IJMREM Page 21
Figure 2:
Figure 2: sample size and power for two stage in phase II
Table (3) sample size in phase III clinical trials:
d n
0.10 0.15 1168 1335
0.15 0.20 1726 2093
0.20 0.25 1917 2474
0.25 0.30 2162 2982
0.30 0.35 2471 3661
0.35 0.40 2469 3950
0.40 0.45 2473 4300
0.45 0.50 2163 4120
0.50 0.55 2178 4796
0.55 0.60 1713 4031
0.60 0.65 1550 4133
0.65 0.70 1281 3942
0.70 0.75 997 3625
0.75 0.80 703 3124
0.80 0.85 432 2471
0.85 0.90 233 1864
0.90 0.95 89 1187